Colorectal cancer is the third most common cancer among men and women in the United States, and is among the most deadly of cancers. In an effort to improve those statistics, doctors began recommending that people have regular colon screenings, such as colonoscopies, to look for signs of the disease. Screenings are recommended beginning at age 50 or earlier for people who have a family history of colorectal cancer or are experiencing symptoms such as blood in the stool.

However, colonoscopies are intimidating. The procedure involves sending a tube with a camera on the end through the rectum and into the large intestines. Patients are sedated during the process, but they must prepare at least a day before the procedure by taking large amounts of laxatives to cleanse the bowel before a colonoscopy.

Between the uncomfortable prep required and the thought of the procedure itself, many people opt to go without. Studies show that less than 20 percent of the people who should be screened for colon cancer actually have a colonoscopy.

Which explains why companies like EDP Biotech are working tirelessly to find a more patient-friendly test. (Not to mention that approval of such a test would mean millions, if not billions, for the company that lands a suitable alternative to colonoscopies.)

EDP Biotech’s ColoMarker test involves adding a chemical to a small blood sample. The reading takes about 30 seconds, and the results are revealed on a computer screen. The test detects a certain marker in the blood that indicates if a patient is clear from colon cancer or needs further testing, perhaps by a colonoscopy.

In tests of 2,400 patients, the ColoMarker detected every case of colon cancer during treatable stages. The company is currently seeking FDA approval and hopes to have the ColoMarker available to the public in one to three years.

Source: WBIR.com

SOURCE: Fleet Attorney › Blood test to detect colon cancer seeks FDA approval

During a colonoscopy, a doctor inserts a long tube with a camera on the end through the rectum and the intestines to look for polyps, signs of early colon cancer. The procedure can virtually remove the risk of colon cancer if detected early, making regular colon screenings a must for individuals age 50 and older and earlier for those with a family history or who are showing signs of colon cancer.

The second bowel cleaning some physicians recommend prior to a colonoscopy follows the day-before rigors of drinking a laxative solution or taking a pill that purges the bowels of its contents. Doctors have found that even after the bowel has been prepped the day before and no more food consumed, sometimes a collection of dead cells, bacterial secretions, mucus, bile and other debris collect in the bowels during the night and can interfere with the physician’s view during the procedure. The second cleansing is usually preformed about five hours before the colonoscopy is scheduled, requiring some patients to wake extra early to “get moving.”

But one word of caution about the bowel cleansing process. Take a close look at the laxative your are prescribed or told to purchase over-the-counter by your doctor. A type of laxative often used to cleanse the bowel before colonoscopies, called oral sodium phosphates, or OSPs, have been linked to serious kidney injury. In some cases, the injury has resulted in kidney failure. The finding has resulted in a black box warning on prescription brands of OSPs, such as Visicol and Osmo Prep, and the removal of over-the-counter Fleet OSPs. If you have experienced kidney injury days, weeks or even months after taking OSP products to cleanse the bowel, you may have a claim against the manufacturer.

Source: Boston.com

SOURCE: Fleet Attorney › Second bowel cleansing recommended for colonoscopies

Currently, C.B. Fleet faces 38 lawsuits that allege the pharmaceutical company did not do enough to warn consumers and health care providers of the risk of serious kidney injury when using its products. The lawsuits were consolidated last week into one federal court to speed the pretrial process.

C.B. Fleet chief scientific officer Chris McDaniel says several thousands of cases of the company’s OSP products have been returned to the company’s Lynchburg, Virginia, headquarters. The company contends that the products are still safe if used as directed, in low doses as a laxative or in higher doses for bowel cleansing prior to procedures such as colonoscopy. In larger doses, the labeling says consumers should drink at least 72 ounces of water to avoid dehydration during use over two days. It also warns individuals who had kidney problems not to use the solutions.

“Fleet’s priority is to ensure the safety of our customers and consumers in general,” McDaniel said. “… We would have to consider whether we felt comfortable that the product would be used safely and according to the labeling that we put out with the product.”

Source: The News & Advance

SOURCE: Fleet Attorney › C.B. Fleet wants to put recalled products back on market